58 results
6-K
EX-1.1
BLRX
Bioline Rx Ltd
7 Mar 14
BioLineRx Closes $24.1 Million Underwritten Public Offering
12:00am
Writing Prospectus that is not an Issuer General Use Free Writing Prospectus.
“Pricing Disclosure Package” means any Issuer General Use Free Writing … a material fact required to be stated therein or necessary to make the statements therein not misleading.
(iii) The Pricing Disclosure Package
6-K
EX-99
BLRX
Bioline Rx Ltd
7 Feb 19
As Representative of the several Underwriters
12:00pm
Prospectus that is not an Issuer General Use Free Writing Prospectus.
“Pricing Disclosure Package” means any Issuer General Use Free Writing Prospectus … Package, as of the Applicable Time, does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make
6-K
EX-10.1
BLRX
Bioline Rx Ltd
17 May 13
BioLineRx Enters into “At-The-Market” Offering
12:00am
Disclosure Package”) as of each Applicable Time and each Settlement Date, will not include any untrue statement of a material fact or omit to state any … or the Prospectus and each such Issuer Free Writing Prospectus, as supplemented by and taken together with the General Disclosure Package
6-K
EX-99
BLRX
Bioline Rx Ltd
21 Jan 21
Amended and Restated Underwriting Agreement
4:32pm
, if any, included on Exhibit D hereto, all considered together (collectively, the “General Disclosure Package”), nor (y) any individual Issuer Limited … Use Free Writing Prospectus, when considered together with the General Disclosure Package, nor (z) any Issuer General Use Free Writing Prospectuses
6-K
EX-1
y4xew2nl5jrjwb9bbeb
28 May 19
Current report (foreign)
7:04am
6-K
EX-99
oq8ysbrw0i36bcoqaxug
27 May 22
2022 Annual General Meeting of Shareholders
4:30pm
6-K
EX-99
dvk1kftl
18 Jan 22
BioLineRx Announces Successful Completion of Pre-NDA
7:11am
6-K
EX-1
99mdf
21 Nov 11
BioLineRx Announces Receipt of Approval in India
12:00am
6-K
EX-99
n13txl nws
16 Oct 12
BioLineRx Announces Successful Completion of Pre-Clinical
12:00am
6-K
EX-99
154of4rtf7ol7f
16 Mar 22
BioLineRx Reports Fourth Quarter 2021 Financial Results
7:11am
6-K
EX-99.2
r0rxo4yt
16 Feb 12
Current Report, Foreign Issuer
12:00am
20-F/A
EX-4.40
ajw5qcopy5
31 May 16
Annual report (foreign) (amended)
12:00am
6-K
EX-99
pxdmx3n
11 May 22
BioLineRx Reports First Quarter 2022 Financial Results
7:14am
6-K
EX-99
6u24l8am0wxqx1gw 42m
16 Aug 22
BioLineRx Reports Second Quarter 2022 Financial Results
7:19am
6-K
EX-99
3x61 ku8so877
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
mhz4jip5enghptxscly
10 Nov 14
BioLineRx Reports Third Quarter 2014 Financial Results
12:00am
6-K
EX-99
7pnbm9s03w4bsobx71l
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am